Research & Discovery
Your Favorite Fishing Stream May be at High Risk From Climate Change – Here’s How to Tell
If communities can figure out where these streams will warm the most, they can plan for the future.
Q&A: College Success for Foster Youth
"Climbing a Broken Ladder: Contributors of College Success for Youth in Foster Care" author talks better support for foster youth
Student Profiles in Pharmaceutical Research – Shipra Malik
Shipra Malik was selected for an oral presentation and a cash prize for the prestigious 2021 RNA Institute Mini-Symposium series.
Student Profiles in Pharmaceutical Research – May Zhang
May's Honors thesis has been published in Biochemical Pharmacology.
UConn-Technion Collaboration Develops Model for Affordable Fuel Cell Catalysts
UConn researchers and collaborators at Technion – Israel Institute of Technology developed a theoretical model that will expediate the development of affordable fuel cells, a key technology for sustainable energy.
Too Hot or Too Cold? UConn Researcher Finds ‘Goldilocks Problem’ in Child Welfare Decision-Making
A major tool widely used in child welfare decision-making - and the way agencies try to implement it - may be hindering social workers.
Connecticut Zoning Atlas Makes the Case for Zoning Reform
The nation's first interactive map letting citizens visualize their town's zoning laws
Meet the Researcher: Caitlin Caspi, College of Agriculture, Health, and Natural Resources
Caspi champions collaboration as the key to her success in researching food security and diet-related health outcomes.
Returning the Favor: UConn Researchers Presented With PPE Supply
UConn researchers who donated personal protective equipment for emergency use early in the pandemic had the favor returned this week.
High-Profile Brain Tumor Therapy Trial Chooses UConn Health
An immunotherapy derived from the polio virus has shown improved survival rates in early-phase trials in patients with an aggressive type of brain tumor known as glioblastoma. UConn Health will be one of a select few sites in the U.S. for the second phase, which will pair it with the cancer immunotherapy pembrolizumab (Keytruda).